Description
Exogenus Therapeutics’ lead product, Exo-101, is an extracellular vesicle–based therapy derived from umbilical cord blood cells and protected by proprietary intellectual property. Preclinical data demonstrate strong therapeutic potential in regenerative medicine, fibrosis and autoimmune disorders. Exo-101 exhibits a multifactorial mechanism of action, simultaneously modulating inflammatory and pro-regenerative processes through targeted effects on key immune cells. The company is preparing European funding applications to strengthen its preclinical data package, initiate a first clinical study and position the technology for future international licensing opportunities.
In parallel, the company wants to diversify its range of products, as well as its areas of business activity, namely through entering non-therapeutic markets. These activities will be financed through instruments dedicated to higher-risk projects, designed for innovative technologies still in the early stages of development. The success of the planned applications will contribute not only to the development of new products but also to the viability of the company in the medium term, as well as to the role it will play in innovation in Portugal and internationally.
